Non-replicating rhabdovirus-derived particles (NRRPs) eradicate acute leukemia by direct cytolysis and induction of antitumor immunity

Blood Cancer Journal

Volumn 3, Issue 7, 2013, Pages

  Batenchuk, C ^a,b   Le Boeuf, F ^a,b   Stubbert, L ^a,b   Falls, T ^a,b   Atkins, H L ^a,b,c   Bell, J C ^a,b   Conrad, D P ^a,b,c  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Acute leukemia; Non replicative rhabdovirus derived particles; NRRP; Oncolytic virus

Indexed keywords

ANTILEUKEMIC AGENT; INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; NON REPLICATING RHABDOVIRUS DERIVED PARTICLE; RANTES; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; BLAST CELL CRISIS; CANCER PATIENT; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DISSEMINATED CANCER; DOSE RESPONSE; HUMAN; IMMUNOMODULATION; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; RHABDOVIRUS; TUMOR IMMUNITY; VIRION; VIRUS PARTICLE;

EID: 84880867454     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2013.23     Document Type: Article

References (30)

1. Stojdl DF, Lichty BD, TenOever BR, Paterson JM, Power AT, Knowles S et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003; 4: 263-275. (Pubitemid 37329791)
2. Lichty BD, Stojdl DF, Taylor RA, Miller L, Frenkel I, Atkins H et al. Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy. Hum Gene Ther 2004; 15: 821-831. (Pubitemid 39244837)
3. Willmon CL, Saloura V, Fridlender ZG, Wongthida P, Diaz RM, Thompson J et al. Expression of IFN-b enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Res 2009; 69: 7713-7720.
4. Brun J, McManus D, Lefebvre C, Hu K, Falls T, Atkins H et al. Identification of genetically modified maraba virus as an oncolytic rhabdovirus. Mol Ther 2010; 18: 1440-1449.
5. Parato KA, Senger D, Forsyth PAJ, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005; 5: 965-976. (Pubitemid 41766784)
6. Melcher A, Parato K, Rooney CM, Bell JC. Thunder and lightning: Immunotherapy and oncolytic viruses collide. Mol Ther 2011; 19: 1008-1016.
7. McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001; 61: 8751-8757. (Pubitemid 34013887)
8. Barber GN. VSV-tumor selective replication and protein translation. Oncogene 2005; 24: 7710-7719. (Pubitemid 41670673)
9. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012; 30: 658-670.
10. Naik S, Russell SJ. Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin Biol Ther 2009; 9: 1163-1176.
11. Bais S, Bartee E, Rahman MM, McFadden G, Cogle CR. Oncolytic virotherapy for hematological malignancies. Adv Virol 2012; 2012: 8.
12. Zeyaullah M, Patro M, Ahmad I, Ibraheem K, Sultan P, Nehal M et al. Oncolytic viruses in the treatment of cancer: a review of current strategies. Pathol Oncol Res 2012; 18: 771-781.
13. Wildner O. Comparison of replication-selective, oncolytic viruses for the treatment of human cancers. Curr Opin Mol Ther 2003; 5: 351-361. (Pubitemid 37080893)
14. Hernández-Alcoceba R. Recent advances in oncolytic virus design. Clin Transl Oncol 2011; 13: 229-239.
15. Galivo F, Diaz RM, Wongthida P, Thompson J, Kottke T, Barber G et al. Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma. Gene Ther 2010; 17: 158-170.
16. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000; 6: 821-825. (Pubitemid 30469434)
17. Le Boeuf F, Batenchuk C, Va?ha?-Koskela M, Breton S, Roy D, Lemay C et al. Model-based rational design of an oncolytic virus with improved therapeutic potential. Nat Commun 2013; 4: 1974.
18. Ebert O, Harbaran S, Shinozaki K, Woo SLC. Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice. Cancer Gene Ther 2005; 12: 350-358. (Pubitemid 40411194)
19. Dinarello CA. Historical insights into cytokines. Eur J Immunol 2007; 37: S34-S45. (Pubitemid 350131266)
20. Luther SA, Cyster JG. Chemokines as regulators of T cell differentiation. Nat Immunol 2001; 2: 102-107. (Pubitemid 33707926)
21. Metcalfe SM. LIF in the regulation of T-cell fate and as a potential therapeutic. Genes Immun 2011; 12: 157-168.
22. Lemay CG, Rintoul JL, Kus A, Paterson JM, Garcia V, Falls TJ et al. Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine. Mol Ther 2012; 20: 1791-1799.
23. Conrad DP, Tsang J, Maclean M, Diallo J, LeBoeuf F, Lemay C et al. Leukemia cell-Rhabdovirus vaccine: personalized immunotherapy for acute lymphocytic leukemia. Clin Cancer Res 2013; epub ahead of print: 10.1158/1078- 0432.CCR-12-3199.
24. Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res 2010; 16: 3100-3104.
25. Finke J, Nagler A. Viewpoint: what is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning - is there still an upper age limit? A focus on myeloid neoplasia. Leukemia 2007; 21: 1357-1362. (Pubitemid 46969869)
26. Daenen S, Van Der Holt B, Dekker AW, Willemze R, Rijneveld AW, Biemond BJ et al. Intensive chemotherapy to improve outcome in patients with acute lymphoblastic leukemia over the age of 40: a phase II study for efficacy and feasibility by HOVON. Leukemia 2012; 26: 1726-1729.
27. Giles FJ, O'Dwyer M, Swords R. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1698-1707.
28. Hehlmann R. How I treat CML blast crisis. Blood 2012; 120: 737-747.
29. Kepp O, Senovilla L, Galluzzi L, Panaretakis T, Tesniere A, Schlemmer F et al. Viral subversion of immunogenic cell death. Cell Cycle 2009; 8: 860-869.
30. Mahoney DJ, Lefebvre C, Allan K, Brun J, Sanaei C, Baird S et al. Virus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell death. Cancer Cell 2011; 20: 443-456.